ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 249 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,129,200 | -78.2% | 60,000 | -81.5% | 0.26% | -79.5% |
| Q4 2022 | $5,174,001 | -2.7% | 325,000 | 0.0% | 1.25% | +17.7% |
| Q3 2022 | $5,317,000 | +11458.7% | 325,000 | +17168.9% | 1.06% | +17566.7% |
| Q1 2022 | $46,000 | +9.5% | 1,882 | +6.6% | 0.01% | 0.0% |
| Q4 2021 | $42,000 | -99.1% | 1,765 | -99.4% | 0.01% | -98.2% |
| Q3 2021 | $4,681,000 | -8.6% | 281,765 | +34.3% | 0.33% | -20.3% |
| Q2 2021 | $5,119,000 | -66.0% | 209,866 | -64.1% | 0.41% | -18.3% |
| Q1 2021 | $15,076,000 | +403.4% | 584,308 | +943.3% | 0.51% | +284.1% |
| Q4 2020 | $2,995,000 | -53.5% | 56,008 | -64.1% | 0.13% | -71.7% |
| Q3 2020 | $6,436,000 | -46.0% | 156,008 | -36.6% | 0.47% | -50.8% |
| Q2 2020 | $11,924,000 | -27.6% | 246,008 | -36.9% | 0.95% | -23.5% |
| Q1 2020 | $16,478,000 | +175.1% | 390,000 | +178.6% | 1.24% | +27.8% |
| Q4 2019 | $5,989,000 | – | 140,000 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |